DBCG: The Danish Breast Cancer Cooperative Group - A 30-year struggle for better breast cancer treatment in Denmark

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 491-496

  Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; DENMARK; EDITORIAL; HEALTH PROGRAM; MEDICAL SOCIETY; PATIENT CARE; POLITICS; PRIORITY JOURNAL; BREAST TUMOR; FEMALE; HISTORY; HUMAN; ONCOLOGY;

ANNIVERSARIES AND SPECIAL EVENTS; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; MEDICAL ONCOLOGY;

EID: 45149118574     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802068607     Document Type: Editorial

References (52)

1. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1.
2. McWhirter, R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Brit J Radiol 1948;21:599-610.
3. Johansen H, Kaae S, Jensen M-B, Mouridsen HT. Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study. Acta Oncol 2008;47:633-38.
4. Nissen-Meyer R, Kjellgren K, Malmio K, Månsson B, Norin T. Surgical adjuvant chemotherapy: Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 1978;41:2088-98.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
6. Fisher B, Jeong JH, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96:1823-31.
7. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: The David A. Karnofsky memorial lecture. Cancer Res 1980;40:3863-74.
8. Einhorn J, Larsson LG. [Neoplasm medical care and radiotherapy organization] Lakartidningen 1970;67:1181-93.
9. Peckham MJ. Clinical oncology: The future of radiotherapy and medical oncology. Lancet 1981;1:886-7.
10. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group - DBCG: History, organisation, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47:497-505.
11. Møller S, Jensen M-B, Ejlertsen B, Bjerre KG, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines programmes of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-24.
12. Mouridsen HT, Bjerre KD, Christiansen P, Jensen M-B, Møller S. Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG registry. Acta Oncol 2008;47:525-36.
13. Talman M-LM, Rasmussen BR, Andersen J, Christensen IJ. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol 2008;47:789-94.
14. Thorpe SM, Poulsen HS, Pedersen KO, Rose C. Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark. Eur J Cancer Clin Oncol 1988;24:1263-9.
15. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
16. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-8.
17. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-53.
18. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268-75.
19. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34.
20. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Lancet 1999;354:1425-30.
21. Overgaard M, Juul Christensen J. Postoperative Radiotherapy in DBCG during 30 Years. Techniques, indications and clinical radiobiological perspectives. Acta Oncol 2008;47:639-53.
22. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005;6:557-65.
23. Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 2007;69:1484-95.
24. Overgaard M, Bentzen SM, Christensen JJ, Madsen EH. The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol 1987;9:1-11.
25. Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. Treatment of morbidity associated with the management of the axilla in breast-conserving therapy. Acta Oncol 2000;39:349-54.
26. Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 2000;39:355-72.
27. Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al. Danish Breast Cancer Cooperative Group (DBCG) and the DBCG Radiotherapy Committee. Cosmetic outcome and breast morbidity in breast-conserving treatment-results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002;41:369-80.
28. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncol 2007;46:525-33.
29. Bentzen SM, Overgaard M. Early and late normal tissue injury after postmastectomy radiotherapy. Recent Results Cancer Res 1993;130:59-78.
30. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol 2005;44:801-15.
31. Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 2008;86:314-20.
32. Alsner J, Andreassen CN, Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008;18:126-35.
33. Jensen AR, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T, Overgaard J. Stage and survival in breast cancer patients in screened and non-screened Danish and Swedish populations. Acta Oncol 2003;42:701-9.
34. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
35. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-22.
36. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, et al. BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-8.
37. Offersen BV, Overgaard M, Kroman K, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: A systematic review. (submitted).
38. Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T, Lykkesfeldt AE. Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncol 2008;47:795-801.
39. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of Topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-90.
40. Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-34.
41. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, et al. Tissue micro arrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591-99.
42. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26:1419-26.
43. Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA. Prediction of metastasis from low-malignant breast cancer by gene expression profiling. Int J Cancer 2007;120:1070-5.
44. Thomassen M, Hansen TvO, Borg Å, Lianee HT, Wikman F, Pedersen IS, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 2008;47:772-77.
45. Offersen BV, Riisbro R, Knoop A, Brünner N, Overgaard J; Danish Breast Cancer Cooperative Group (DBCG) Tumor Biology Committee. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. Acta Oncol 2007;46:782-91.
46. Würtz SØ, Schrohl A-S, Mouridsen H, Brünner N. TIMP-1 as a tumor marker in breast cancer - An update. Acta Oncol 2008;47:580-90.
47. Offersen BV, Alsner J, Olsen KE, Riisbro R, Brunner N, Sørensen FB, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47:618-32.
48. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børrensen-Dale A-L, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008;47:600-7.
49. Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M, et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol 2008;47:239-47.
50. Friis E, Galatius H, Garne JP. Organized nation-wide implementation of sentinel lymph node biopsy in Denmark. Acta Oncol 2008;47:556-60.
51. Christiansen P, Friis E, Balslev E, Jensen D, Møller S. Sentinel node biopsy in breast cancer: Five years experience from Denmark. Acta Oncol 2008;47:561-68.
52. Klinisk kræftforskning i Danmark. KOF-udvalget nedsat af Statens Sundhedsvidenskabelige Forskningsråd. Forskningsstyrelsen 2004; pp 1-67.